Penn Medicine 2020 Updates in Oncology
2020 ASCO Update on Lymphomas: Should Pembro Be New SoC in R/R cHL? Is Axicabtagene Ciloleucel Effective and Durable in R/R Indolent Non-Hodgkin Lymphoma?
By
Penn Medicine 2020 Updates in Oncology
FEATURING
James Gerson
By
Penn Medicine 2020 Updates in Oncology
FEATURING
James Gerson
Login to view comments.
Click here to Login